YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Potential Hypersensitivity of Recombinant Mouse IL-2 as a Immunotherapeutic Agent of Cancer in Tumor-bearing BALB/c Mice

항암 면역요법제 인터루킨-2의 면역과민반응 평가연구

  • Cho, Young-Joo (Department of Toxicology, National Institute of Toxicological Research, Korea Food Drug Administration) ;
  • Eom , Juno H. (Department of Toxicology, National Institute of Toxicological Research, Korea Food Drug Administration) ;
  • Gil , Jung-Hyun (Department of Toxicology, National Institute of Toxicological Research, Korea Food Drug Administration) ;
  • Park , Jae-Hyun (Department of Toxicology, National Institute of Toxicological Research, Korea Food Drug Administration) ;
  • Lee , Jong-Kwon (Department of Toxicology, National Institute of Toxicological Research, Korea Food Drug Administration) ;
  • Oh , Hye-Young (Department of Toxicology, National Institute of Toxicological Research, Korea Food Drug Administration) ;
  • Park , Kui-Lea (Department of Toxicology, National Institute of Toxicological Research, Korea Food Drug Administration) ;
  • Kim , Hyung-Soo (Department of Toxicology, National Institute of Toxicological Research, Korea Food Drug Administration)
  • 조영주 (독성연구부 면역독성과, 국립독성연구원) ;
  • 엄준호 (독성연구부 면역독성과, 국립독성연구원) ;
  • 길정현 (독성연구부 면역독성과, 국립독성연구원) ;
  • 박재현 (독성연구부 면역독성과, 국립독성연구원) ;
  • 이종권 (독성연구부 면역독성과, 국립독성연구원) ;
  • 오혜영 (독성연구부 면역독성과, 국립독성연구원) ;
  • 박귀례 (독성연구부 면역독성과, 국립독성연구원) ;
  • 김형수 (독성연구부 면역독성과, 국립독성연구원)
  • Published : 2004.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

Interleukin-2 (IL-2), a glycoprotein mainly secreted by CD4+ T helper Iymphocytes, has been developed to use recombinant cytokine to augment the immune response against cancer since IL-2 not only stimulates T Iymphocytes but also enhances natural killer (NK) cell activity. In order to evaluate the immunological safety of recombinant mouse IL-2 (rmIL-2) in cancer therapy, renal cell carcinoma was established in the flank by s.c. injection of renca cell line. Tumor-bearing BALB/c mice were treated with I.p. injections with $2{\times}10^5$ Lu rmIL-2. Even though the tumor size was diminished, there were not significant recovery of body and relative lymphoid organ weights including thymic atrophy in rmIL-2 immunotherapy. Distribution ratios of T cell subsets in thymus were analysed using flow cytometry. Without regard to dosage of rmIL-2, the ratio of CD3+CD4-CD8- T cells was increased in accordance with survival of solid tumor but that of CD4+CD8+ T cells was decreased dramatically. Emergence of autoantibodies (ANA, anti-dsDNA, and anti-histone) in blood was measured after rmIL-2 treatment. The results showed that the levels of ANA and anti-dsDNA did not significantly changed, but the level of anti-histone was increased significantly owing to rmIL-2 therapy. These results indicate rmIL-2 immunotherapy is to induce the autoimmune potential, and the anti-histone measurement as a biomarker of autoimmunity is useful in cancer immunotherapy.

Keywords

References

  1. Rosenberg, S. A. and Longo, D. L. : Principles and application of biologic therapy. In : DeVita, V. T., Hellman, S. and Rosenberg, S. A., Cancer 3rd ed., Philadelphia Loppincott, p. 301 (1989)
  2. Roitt, I. M., Brostoff, J. and Male, D. : Immunology. 1st ed., London, Mosby, p. 18 (1985)
  3. Herberman, R. B. : Design of clinical trials with biological response modifiers. Cancer Treat. Rep. 24, 1161 (1985)
  4. Jang, J. S., Jun, J. B., Hahm, J. S., Lee, M. H., Choi, I. Y. and Chung, A. J. : Clinical trial of human recombinant interleukin-2 (IL-2) in advanced cancer patients. J. of Korean Cancer Association 22, 96 (1990)
  5. Yomohide, T., Tetsuo, T., Tatsuya, K., Takuya, M., Noriyoshi, K., Yoshiko, S., Masahisa, J., Akinori, K., Yutaka, S., Masatsugu, H. and Norio, H. : Administration of interleukin-12 enhances the therapeutic efficacy of dentritic cell-based tumor vaccines in mouse hepatocellular carcinoma. Cancer Research 61, 7563 (2001)
  6. Bing, C., Tatyana, M. T., Daila, S. G., Melba, L. A., Radha, D. R. and Istvan, F. : Evaluation of cytokine toxicity induced by vaccinia virus-mediated IL-2 and IL-12 antitumor immunotherapy. Cytokine 15, 305 (2001) https://doi.org/10.1006/cyto.2001.0906
  7. Shinichiro, I., Setsu, M., Chie, K.,Yoichiro, M., Takeshi, Y. and Motoo, S. : Combination chemo-immunotherapy of murine solid tumor with OK-432, G-CSF, IL-2, and chemotherapeutics. Int. J. Immunopharmac. 17, 973 (1995) https://doi.org/10.1016/0192-0561(95)00098-4
  8. Stephane Palu, Etienne Regulier, Yves Poitevin, Horst Hormann, and R. Brice Acres : The combination of a chemokine, cytokine and TCR-based T cell stimulus for effective gene therapy of cancer. cancer Immunol. Immunother. 51, 645 (2002) https://doi.org/10.1007/s00262-002-0314-2
  9. Lee, J.K.,Thomas, J. S., Alan, D. B., Timothy, C. B., Howard, A. Y., Kristin, L. K., Jon, M. W. and Robert, H. W. : IFN-${\gamma}$-dependent delay of in vivo tumor progression by FAS over expression on murine renal cancer cells. The Journal of Immunolgy 164, 231 (2000) https://doi.org/10.4049/jimmunol.164.1.231
  10. Kang, C. D. : 종양 면역 치료법의 최신 연구 동향, 보건산업기술동향, p. 50 (2001)
  11. Morgan, D. A., Ryscetti, F. W. and Gallo, R. C. : Selective in vitro growth of T lymphocytes from normal bone marrows. Science 193, 1007 (1976) https://doi.org/10.1126/science.181845
  12. Papa, M. Z., Yang, J. C., Vetto, J. T., Shiloni, E., Eisenthal, A. and Rosebberg, S. A. : Combined effects of chemotherapy and IL-2 in the therapy of mice with advanced pulmonary tumors. Cancer Research 48, 122 (1988)
  13. NIH conference : Immunomodulator in clinical medicine. Annal. Int. Med. 106, 421 (1987)
  14. Anton, H. C. Baselmans, J.-W., Koten, J. J., Battermann, J. E., Van, D. and Willem, D. O. : The mechanism of regression of solid SL2 lymphosarcoma after local IL-2 therapy. Cancer Immunol. Immunother. 51, 492 (2002) https://doi.org/10.1007/s00262-002-0306-2
  15. Kim, K. Y., Cho, Y. J., Jeon, G. A., Ryu, P. D. and Nam, M. J. : Membrane-bound alkaline phosphatase gene induces anti-tumor effect by G2/M arrest in etoposide phosphate-treated cancer cells. Molecular and Cellular BiochemistryI 252, 213 (2003) https://doi.org/10.1023/A:1025572815125
  16. Samir, S. T., William, P., Robert, F. and Arie, B. : Immunotherapy for renal cell carcinoma : The era of interleukin-2-based treatment. Urology 45, 911 (1995) https://doi.org/10.1016/S0090-4295(99)80108-3
  17. Talmadge, J. E., Philips, R., Schindler, J., Tribble, H. and Pennington, R. : Systemic preclinical study on the therapeutic properties of recombinant human interleukin-2 for the treatment of metastatic disease. Cancer Research 47, 5725 (1987)
  18. Lotze, M. T., Chang, A E., Seipp, C. A., Vetto, J. T. and Rosenberg, S. A. : High dose recombinant IL-2 in the treatment of patients with disseminated cancer. JAMA 256, 3117 (1986) https://doi.org/10.1001/jama.256.22.3117
  19. Fu, Y., Paul, R. D., Wang, Y. and Lopez, D.M. : Thymic atrophy induced by murine mammary adenocarcinoma in vivo. In Vivo 3, 4300 (1989)
  20. Becky Adkins, Vijaya Charyulu, Qi-Ling Sun, David Lobo, and Diana M. Lopez : Early block in maturation is associated with thymic involution in mammary tumor-bearing mice. The Journal of Immunology 164, 5635 (2000)
  21. Nitin, J. K., Carol, L. V., Jeffrey, A. B. and Stephen, D. M. : Targeting the B7/CD28 : CTLA-4 costimulatory system in CNS autoimmune disease. J. of Neuroimmunology 89, 10 (1998)
  22. Maria A Curotto de Lafaille and Juan J Lafaille : CD4+ regulatory T cells in autoimmunity and allergy. Current Opinion in Immunology 14, 771 (2002)
  23. Ethan M. Shevach : Suppressor T cells: Rebirth, function and homeostasis. Current Biology 10, R572 (2000)
  24. John J. O'Shea, Averil Ma and Peter Lipsky : Cytokines and autoimmunity. Nature Reviews Immunology 2, 37 (2002)
  25. Mayer Fishman and John Seigne : Immunotherapy of metastatic renal cell cancer. Cancer Control 9, 293 (2002)
  26. Paula, G. E, Seward, B. R., Jean, K. M., Mary, F., Marie, E. C., Mary, E. P., Michael, B. A. and Jared, A. G. : Induction of myasthenia gravis, myositis and insulin-dependent diabetes mellitus by high-dose interleukin-2 in a patient with renal cell cancer. J. of Immunotherapy 25, 373 (2002)
  27. Bondanza, A., Zimmermann, V. S., Dell'Antonio, G., Cin, E. D., Capobianco, A., Sabbadini, M. G., Manfredi, A. A. and Querini, P. R. : Cutting Edge: Dissociation between autoimmune response and clinical disease after vaccination with dendritic cells. J. of Immunology 170, 24 (2003)